LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Flow Cytometry Stem Cell Enumeration Kit Designed to Ease Stem Cell Transplantation

By LabMedica International staff writers
Posted on 07 Mar 2012
Image: The BD Stem Cell Enumeration (SCE) Kit (Photo courtesy of BD Biosciences).
Image: The BD Stem Cell Enumeration (SCE) Kit (Photo courtesy of BD Biosciences).
A dedicated flow cytometry stem cell enumeration kit is aimed at the rapidly growing stem cell transplantation market.

High-dose chemotherapy (HDC) with transplant is now standard therapy in multiple myeloma, acute myeloid leukemia in first remission, and intermediate-grade non-Hodgkin's lymphoma. Stem cell transplantation with cell selection is performed after HDC in an effort to restore a cancer patient’s blood and immune cell production capacity, which is destroyed in this aggressive form of cancer treatment. Improvements in transplantation techniques, including the wider use of cell selection, have also contributed to a significant reduction in the morbidity and mortality associated with conventional transplantation. As a result, HDC with transplantation has grown at an average annual rate of 21% over the past 10 years.

To aid clinicians and researchers working in the stem cell transplantation field BD Biosciences (Franklin Lakes, NJ, USA) has introduced their BD Stem Cell Enumeration (SCE) Kit for use on the BD FACSCanto II and BD FACSCalibur flow cytometers.

The SCE Kit is for in vitro diagnostic use and provides a single-tube, single-platform assay for accurate, reproducible, and rapid enumeration of CD34+ hematopoietic and progenitor cells in a wide range of stem cell sources. Sample types that may be analyzed with the SCE Kit include normal and mobilized peripheral blood, material from fresh or frozen leukophoresis, bone marrow, and cord blood.

The BD SCE assay allows simultaneous enumeration of total viable dual-positive CD45+/CD34+ hematopoietic stem cells in absolute counts of CD34+ cells/microliter and the percentage of viable leucocytes (CD45+) that are CD34-positive (CD34+). A set of premixed antibodies reduces reagent preparation time to meet productivity demands of clinical labs. In addition, the SCE assay incorporates BD’s proprietary Trucount tubes, which allow determination of absolute cell count, thereby eliminating variability associated with hematology-derived absolute counts.

Related Links:

BD Biosciences



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Collection and Transport System
PurSafe Plus®
Hemodynamic System Monitor
OptoMonitor
New
Gold Member
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000

Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more